India Active Pharmaceutical Ingredients Market: A Promising Growth Landscape during the forecast Period 2021-2028
![]() |
Active Pharmaceutical Ingredients Market |
The India Active Pharmaceutical Ingredients (API) market is
witnessing a promising growth landscape driven by various factors. API forms a
crucial component of pharmaceutical manufacturing, serving as the primary
active substance responsible for therapeutic effects in medications. With India
being a global hub for generic drug production and a major player in the
pharmaceutical industry, the API market in the country has gained significant
traction in recent years. This article delves into the dynamics of the India
API market, exploring its growth drivers, market trends, regulatory landscape, and
future prospects.
API market is propelled by the rising demand for generic
medicines worldwide. As a cost-effective alternative to branded drugs, generics
have gained popularity due to their affordability and comparable efficacy. With
India's strong expertise in generic drug manufacturing, the API market has
experienced a surge in demand, as it serves as the backbone for generic
pharmaceutical production.
The Study By Coherent
Market Insights Says, The India Active Pharmaceutical Ingredients Market Is Estimated To Be Valued At US$ 19,993.2 Million In 2021 And Is
Expected To Exhibit A CAGR Of 8.3% During The Forecast Period (2021-2028).
The Indian government has implemented several initiatives to
promote the growth of the pharmaceutical industry, including the API sector.
The "Make in India" campaign, which aims to boost domestic
manufacturing, has provided impetus to API production within the country.
Additionally, initiatives like the Production Linked Incentive (PLI) scheme and
the creation of dedicated API parks have attracted investments and fostered an
enabling environment for API manufacturers.
India's API market enjoys a competitive advantage in terms of
cost. The country offers a cost-effective manufacturing base for API
production, including lower labor costs and access to affordable raw materials.
This cost competitiveness has made India an attractive destination for
outsourcing API production, driving the growth of the market.
India has emerged as a leading exporter of pharmaceutical
products, including APIs. The country's strong manufacturing capabilities,
adherence to international quality standards, and vast product portfolio have
fueled its exports to various countries. The expanding global pharmaceutical
market presents significant opportunities for India's API sector, with
increasing demand from both developed and emerging economies.
Advancements in technology have played a crucial role in
enhancing the API manufacturing process. Automation, process optimization, and
the adoption of advanced techniques have improved production efficiency,
reduced costs, and ensured compliance with stringent quality standards. Indian
API manufacturers have embraced these technological advancements, further
boosting the growth of the market.
Top Companies involved
are Teva
Pharmaceutical Industries Ltd., Solara ,
Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Lupin Limited, Sun
Pharmaceutical Industries Limited, Divi’s Laboratories Ltd., Aarti Drugs Ltd.,
Hikal Ltd., Neuland Labs, Century Pharmaceuticals Ltd., Proventus Life Sciences
Pvt Ltd, Chiral Drugs Pvt Ltd, USV Private Limited, and ASolution
Pharmaceuticals Pvt. Ltd.
Comments
Post a Comment